MVP protocol 2

chemotherapy protocol consisting of above compounds; used in treatment of non-small cell bronchogenic carcinoma

Also Known As:

MVP II protocol; MVP combination

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Therapy Context: Research Results

Therapeutics: 1158551
- Drug Therapy: 293145
  - Combination Drug Therapy: 12066
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - MVP protocol 2: 3
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - MVP protocol 2: 3
- Clinical Protocols
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - MVP protocol 2: 3
Inorganic Chemicals: 9
Organic Chemicals: 133
- Quinones: 434
  - Indolequinones: 12
    - Mitomycins: 11
      - MVP protocol 2: 3
Heterocyclic Compounds: 198

Experts

1.	Asamoto, Hitoshi: 1 article (10/2003)
2.	Ishiguro, Takashi: 1 article (10/2003)
3.	Kawahara, Masaaki: 1 article (10/2003)
4.	Maeda, Hajime: 1 article (10/2003)
5.	Ogawara, Mitsumasa: 1 article (10/2003)
6.	Sawa, Toshiyuki: 1 article (10/2003)
7.	Yamamoto, Satoru: 1 article (10/2003)
8.	Yokota, Souichiroh: 1 article (10/2003)
9.	Yoshida, Tsutomu: 1 article (10/2003)

Related Diseases

1.	Large Cell Carcinoma 10/01/2003 - "Postoperative complications and pathological pulmonary toxicity were investigated in 7 surgical patients out of 306 enrolled patients who were treated with MVP combination chemotherapy and concurrent or sequential thoracic radiotherapy of 56 Gy. The 7 patients were 45-66 years old (median 50 years old), with 4 of stage IIIA, 3 of stage IIIB, 4 with adenocarcinoma, 2 with squamous cell carcinoma, and 1 with large cell carcinoma. "
2.	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/01/2003 - "Postoperative complications and pathological pulmonary toxicity were investigated in 7 surgical patients out of 306 enrolled patients who were treated with MVP combination chemotherapy and concurrent or sequential thoracic radiotherapy of 56 Gy. The 7 patients were 45-66 years old (median 50 years old), with 4 of stage IIIA, 3 of stage IIIB, 4 with adenocarcinoma, 2 with squamous cell carcinoma, and 1 with large cell carcinoma. "
3.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/01/1990 - "Twelve patients with advanced inoperable non-small cell lung cancer (NSCLC) were treated with mitomycin, vinblastine and cisplatin (MVP) combination chemotherapy. " 06/01/1990 - "Preliminary experience with mitomycin, vinblastine and cisplatin (MVP) combination chemotherapy in the treatment of advanced non-small cell lung cancer at University Hospital, Kuala Lumpur."
4.	Adenocarcinoma 10/01/2003 - "Postoperative complications and pathological pulmonary toxicity were investigated in 7 surgical patients out of 306 enrolled patients who were treated with MVP combination chemotherapy and concurrent or sequential thoracic radiotherapy of 56 Gy. The 7 patients were 45-66 years old (median 50 years old), with 4 of stage IIIA, 3 of stage IIIB, 4 with adenocarcinoma, 2 with squamous cell carcinoma, and 1 with large cell carcinoma. "
5.	Pathologic Complete Response 09/01/1993 - "We have identified and reviewed the course of 21 patients with advanced NSCLC who achieved a pathologic complete response following a median of three preoperative MVP combination chemotherapy courses including vinblastine or vindesine, cisplatin (120 mg/m2), and mitomycin (n = 19). "

Related Drugs and Biologics

1.	Mitomycin (Mitomycin-C)
2.	Vinblastine (Vinblastine Sulfate)
3.	Cisplatin (Platino)
4.	Vindesine (Vindesin)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Radiotherapy